Abstracts tagged "Fibroblasts, Dermal"

Abstract Number: 2473 • ACR Convergence 2024
Criterion Validity of Modified Rodnan Skin Score: Does It Capture Skin Thickness or Hardening? Results of a Large Skin Histology Study
Shervin Assassi¹, Ruhani Desai², Jeffrey Browning³, Samuel Theodore¹, Meng Zhang¹, Brian Skaug¹, Jerry Alonso¹, Zsuzsanna McMahan¹, Maureen Mayes¹ and Minghua Wu¹, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston Division of Rheumatology, DeLand, FL, ³Boston University, Cambridge, MA
Background/Purpose: Modified Rodnan Skin Score is a widely used outcome measure for skin involvement in systemic sclerosis (SSc). Its criterion validity (comparison to the gold…
Abstract Number: 0970 • ACR Convergence 2024
Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity
Rebecca Ross¹, Poli Adi Narayanna Reddy², Joseph Salvino², Elton Zeqiraj³ and Francesco Del Galdo³, ¹Medicine and Health, University of Leeds, Leeds, United Kingdom, ²The Wistar Institute, Philadelphia, PA, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Increased Type I IFN activation plays a key role in Scleroderma (SSc), Systemic Lupus Erythematosus and Inflammatory Myositis. Deubiquitylase (DUB) BRCC36 isopeptidase complex (BRISC)…
Abstract Number: 2643 • ACR Convergence 2024
Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
Kristina Clark¹, Corrado Campochiaro², Emma Derrett-Smith³, Voon Ong⁴, Christopher Buckley⁵ and Christopher Denton⁶, ¹University of Oxford, Oxford, United Kingdom, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³University College London Division of Medicine, Birmingham, United Kingdom, ⁴University College London, London, England, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁶University College London, Northwood, United Kingdom
Background/Purpose: Myofibroblasts are key cells in the pathogenesis of systemic sclerosis (SSc). TGFβ is a key growth factor driving myofibroblast formation in SSc. The main…
Abstract Number: 1643 • ACR Convergence 2024
Single Nuclei Multiome and Spatial Transcriptomic Analysis of Early, Untreated SSc Skin Identifies Signaling Interactions Between Macrophages and Fibroblasts
Helen Jarnagin¹, Dillon Popovich², Rezvan Parvizi³, Rosemary Gedert⁴, Lam C. Tsoi⁵, Rachael Wasikowski⁵, Zhiyun Gong¹, Madeline Morrisson⁶, Laurent Perreard⁷, Fred Kolling IV⁷, Dinesh Khanna⁴, Johann Gudjonsson⁴ and Michael Whitfield³, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, West Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴University of Michigan, Ann Arbor, MI, ⁵Michigan, Dept. of Dermatology, Ann Arbor, MI, ⁶Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁷Geisel School of Medicine, Dartmouth College, Lebanon
Background/Purpose: We generated a vertically integrated dataset on treatment naïve patients with dcSSc (diffuse Systemic Sclerosis) skin that includes bulk RNA-seq, single nuclei multiome, and…
Abstract Number: 2644 • ACR Convergence 2024
Baseline Fibroblast Immunophenotype Predicts Clinical Improvement Among Individuals with Early Diffuse Cutaneous Systemic Sclerosis
Kimberly Lakin¹, Robert Spiera², John Spivack¹, Yaxia Zhang¹, Jessica Gordon³ and dana Orange⁴, ¹Hospital for Special Surgery, New York, NY, ²Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ³Division of Rheumatology, Weill Cornell Medical College, New York, NY, ⁴Rockefeller University, New York, NY
Background/Purpose: We have previously shown that fibroblast CD34 is low and alpha-smooth muscle actin (aSMA) is high in severe diffuse cutaneous systemic sclerosis (dcSSc) skin,…
Abstract Number: 1770 • ACR Convergence 2024
Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus
Nalani Sachan¹, Christina Firl², Philip Carlucci³, Nicola Fraser², Robert Clancy⁴ and Jill Buyon⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL), driven by fetal exposure to maternal anti-SSA/Ro autoantibodies, typically results in permanent cardiac manifestations in utero and/or a transient rash postnatally.…
Abstract Number: 1815 • ACR Convergence 2024
Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel
Lauren Reinke-Breen¹, Laura Leys¹, Sunhwa Kim², Lauren Olson¹, Anastasia Marinopoulos¹, Chris Butler¹, Jennifer Van Camp¹ and Lisa Hazelwood¹, ¹AbbVie, North Chicago, IL, ²AbbVie, South San Francisco, CA
Background/Purpose: Systemic sclerosis (SSc) is a chronic, progressive autoimmune disorder with significant morbidity and mortality. The lack of effective therapies for SSc is, in part,…
Abstract Number: 1818 • ACR Convergence 2024
Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin
Banafsheh Nazari¹, Tracy Tabib², Christina Morse³ and Robert Lafyatis², ¹UPMC-Mercy, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Our previous single-cell RNA-sequencing study identified two major fibroblast subpopulations in healthy skin biopsies: SFRP2/DPP4 and FMO1/LSP1 fibroblasts¹. Additionally, we discovered that adventitial fibroblasts…
Abstract Number: 0957 • ACR Convergence 2023
Rationale for Targeting Insulin-like Growth Factor Signalling in Systemic Sclerosis
Voon Ong¹, Shiwen Xu², Li Xue², Brajesh Kumar³ and Christopher Denton², ¹UCL Medical School Royal Free Campus, London, United Kingdom, ²University College London, London, United Kingdom, ³Horizon Therapeutics, South San Francisco, CA
Background/Purpose: Previous studies have shown that insulin like growth factor (IGF) pathways may promote extracellular matrix deposition and be upregulated in systemic sclerosis (SSc). Teprotumumab,…
Abstract Number: 0960 • ACR Convergence 2023
MiR-3606-3p Alleviates Skin Fibrosis by Suppressing Fibroblast Inflammation and Migration via Inhibiting GAB1 and ITGAV
yahui chen¹, Mengkun shi¹, Wei Wang¹, Chenyi Shi¹, Xueyi Xia¹, wenyu Wu², Jiucun Wang³ and Xiangguang Shi³, ¹Fudan University, Shanghai, China, ²Huashan Hospital, Shanghai, China, ³Shanghai, Shanghai, China
Background/Purpose: Systemic sclerosis (SSc) and keloid are typical skin fibrotic diseases with unclear epigenetic mechanisms and clinical targets. As an important epigenetic regulatory factor, microRNAs…
Abstract Number: 0085 • ACR Convergence 2023
Fibroblasts Promote Upregulation of Cannabinoid Type 2 Receptor on Inflammatory Cells in Dermatomyositis
DeAnna Diaz¹, Muhammad Bashir¹, Rohan Dhiman², Avital Baniel¹, Julianne Kleitsch¹, Rachita Pandya¹, Meena Sharma¹, Thomas Vazquez¹, Ming-Lin Liu², Mariko Momohara² and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. The activation of CB2R has been shown to reduce several,…
Abstract Number: 0963 • ACR Convergence 2023
Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis
Maithri Aspari¹, Josephine Geertsen Keller-Socin¹, Stinne Greisen², Esben Naeser³, Klaus Soendergaard⁴, Birgitta R Knudsen⁵, Voon Ong⁶, Christopher Denton⁷, David Abraham⁷ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University/Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Institute for molecular Biology, Aarhus University, Aarhus, Denmark, ⁶UCL Medical School Royal Free Campus, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: The presence of autoantibodies, especially directed towards topoisomerase I (ATA), in diffuse cutaneous Systemic Sclerosis (dcSSc) is known to be associated with severe clinical…
Abstract Number: 0787 • ACR Convergence 2023
Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry
Kristina Clark¹, Shiwen Xu², Voon Ong³, Christopher Buckley⁴ and Christopher Denton², ¹Barts Health NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³UCL Medical School Royal Free Campus, London, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: We previously described distinct migratory and resident fibroblast populations from lesional skin biopsies in SSc patients. Both populations are profibrotic compared with those from…
Abstract Number: 0964 • ACR Convergence 2023
Systemic Sclerosis (SSc) Dermal Fibroblasts Show Shortened Primary Cilia Due to Aberrant Aurora a Kinase Activation Independently of Transforming Growth Factor β Signalling
Rebecca Wells¹, Rebecca Ross², Alex Timmis¹, Ioanna Georgiou¹, Colin Johnson¹, Natalia Riobo-Del Galdo¹ and Francesco Del Galdo³, ¹University of Leeds, Leeds, United Kingdom, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disorder characterised by abnormal activation of tissue fibroblasts, resulting in tissue and vascular fibrosis of the skin and…
Abstract Number: 0892 • ACR Convergence 2023
Single-Cell RNA Sequencing Reveals Keratinocytes and Fibroblasts Drive Hippo and TGFb Dysregulation and Fibrosis in Epidermal Overexpression of VGLL3 in Cutaneous Lupus
Mehrnaz Gharaee-Kermani¹, Allison Billi¹, Jacob Martens¹, Marisa Hildebrandt¹, Amanda Victory¹, Mitra Maz², Shannon Loftus¹, J. Michelle Kahlenberg¹ and Johann E. Gudjonsson¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Fibrosis is characterized by collagen deposition, fibro/myofibroblast (MYOFB) accumulation, and extracellular matrix remodeling. In some subtypes of cutaneous lupus erythematosus (CLE), particularly discoid lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.